30-Mar-2026
TipRanks (Thu, 26-Mar 4:25 PM ET)
ONC Delivers Robust Revenue Growth and Pipeline Progress Amid Record Free Cash Flow
Market Chameleon (Thu, 26-Feb 3:40 AM ET)
Business Wire (Thu, 26-Feb 6:00 AM ET)
BeOne Medicines to Present at Upcoming Investor Conferences
Business Wire (Tue, 17-Feb 6:00 AM ET)
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26
Business Wire (Wed, 11-Feb 6:00 AM ET)
Business Wire (Tue, 13-Jan 6:00 AM ET)
Market Chameleon (Wed, 7-Jan 4:03 AM ET)
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
Business Wire (Tue, 6-Jan 1:30 PM ET)
ZIIHERA-Based Regimens Set to Redefine First-Line HER2-Positive Gastric Cancer Treatment
Market Chameleon (Mon, 17-Nov 4:02 AM ET)
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
Beone Medicines Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ONC.
As of March 30, 2026, ONC stock price climbed to $284.08 with 147,067 million shares trading.
ONC has a beta of 0.62, meaning it tends to be less sensitive to market movements. ONC has a correlation of 0.06 to the broad based SPY ETF.
ONC has a market cap of $31.53 billion. This is considered a Large Cap stock.
Last quarter Beone Medicines Ltd. - American Depositary Shares reported $1 billion in Revenue and $1.95 earnings per share. This beat revenue expectation by $45 million and exceeded earnings estimates by $.53.
The top ETF exchange traded funds that ONC belongs to (by Net Assets): IBB, FBT, CGGE, BBH, CGIE.
ONC has underperformed the market in the last year with a return of +6.2%, while SPY returned +15.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ONC shares. However, ONC has outperformed the market in the last 3 month and 2 week periods, returning -6.8% and -1.9%, while SPY returned -7.7% and -5.3%, respectively. This indicates ONC has been having a stronger performance recently.
ONC support price is $276.12 and resistance is $289.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONC shares will trade within this expected range on the day.